{
    "SPADE_UN_27847": {
        "Sequence Information": {
            "Peptide Name": "Cathelicidin-BF-15 -AMD",
            "Sequence": "VKRFKKFFRKLKKSV",
            "Sequence Length": 15,
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anticancer",
                "Antifungal",
                "Anti-Mammalian Cell"
            ],
            "Binding Target": "1. Lipid Bilayer",
            "Source": "",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [
                {
                    "uniprotId": "B6D434",
                    "uniprotUrl": "http://www.uniprot.org/uniprot/B6D434",
                    "description": "The amino acid sequence of the current peptide coincides with the part of the UniProt entry that represents a peptide precursor."
                }
            ],
            "Literature": [
                {
                    "Title": "Structure-activity relationships of a snake cathelicidin-related peptide, BF-15.",
                    "Pubmed ID": "22008732",
                    "Reference": "Peptides. 2011;32:2497-2503",
                    "Author": "Chen W, Yang B, Zhou H, Sun L, Dou J, Qian H, Huang W, Mei Y, Han J",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/22008732"
                },
                {
                    "Title": "Aliphatic acid-conjugated antimicrobial peptides - potential agents with anti-tumor, multidrug resistance-reversing activity and enhanced stability.",
                    "Pubmed ID": "26083110",
                    "Reference": "Org Biomol Chem. 2015;13:7673-7680",
                    "Author": "Deng X, Qiu Q, Ma K, Wang X, Huang W, Qian H",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/26083110"
                },
                {
                    "Title": "A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis.",
                    "Pubmed ID": "26881456",
                    "Reference": "J Med Chem. 2016;59:1791-1799",
                    "Author": "Jin L, Bai X, Luan N, Yao H, Zhang Z, Liu W, Chen Y, Yan X, Rong M, Lai R, Lu Q",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/26881456"
                }
            ],
            "Mass": 1939.44,
            "PI": 12.0,
            "Net Charge": 8,
            "Hydrophobicity": -0.84,
            "Frequent Amino Acids": "KFR",
            "Absent Amino Acids": "ACDEGHIMNOPQTUWY",
            "Basic Residues": 8,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 6,
            "Polar Residues": 9,
            "Positive Residues": 8,
            "Negative Residues": 0,
            "SPADE ID": "SPADE_UN_27847",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_06429",
                    "Similarity": 1.0,
                    "Sequence": "LVKRFKKFFRKLKKSVLL"
                },
                {
                    "SPADE_ID": "SPADE_N_06432",
                    "Similarity": 1.0,
                    "Sequence": "VKRFKKFFRKLKKSVL"
                },
                {
                    "SPADE_ID": "SPADE_N_06433",
                    "Similarity": 1.0,
                    "Sequence": "VKRFKKFFRKLKKSVLL"
                }
            ],
            "Hemolytic Activity": "Human gastric epithelial cells GES-1:IC50=87.2±9.1 µM,Human embryonic kidney HEK293 cells:IC50=72.7±6.3 µM,Human erythrocytes:50% Hemolysis=>320 µg/ml,Human erythrocytes:10% Hemolysis=320 µg/ml",
            "Target Organism": "Escherichia coli ATCC 25922(MIC=4µg/ml),Staphylococcus aureus ATCC 25923(MIC=1µg/ml),Pseudomonas aeruginosa ATCC 27853(MIC=32µg/ml),Candida albicans ATCC 90028(MIC=64µg/ml),Escherichia coli(MIC=16µg/ml),Staphylococcus aureus(MIC=16µg/ml),Pseudomonas aeruginosa(MIC=16µg/ml),Salmonella enterica subsp. enterica serovar Typhi(MIC=2µg/ml),Bacillus subtilis(MIC=64µg/ml),Enterobacter cloacae(MIC=8µg/ml),Human breast adenocarcinoma MCF-7(IC50=20.4±3.8µM),Human breast adenocarcinoma MCF-7/Taxol(IC50=21.3±2.7µM),Human myelogenous leukemia K562(IC50=26.3±3.3µM),Human myelogenous leukemia K562/ADM(IC50=28.2±4.2µM),Human prostate cancer DU145(IC50=23.5±4.4µM),Escherichia coli ATCC 25922(MIC=18.75µg/ml),Staphylococcus aureus ATCC 2592(MIC=>100µg/ml),Bacillus subtilis(MIC=75.0µg/ml),Candida albicans ATCC 2002(MIC=18.75µg/ml)"
        }
    }
}